Patents Represented by Attorney Ann Marie Szczepanik

Find this attorney in the Justia Lawyer Directory

  • Transgenic animals exhibiting major disorders related to Alzheimer's disease
    Patent number: 7700823
    Abstract: The present invention relates to nonhuman transgenic animals exhibiting major disorders related to Alzheimer's disease. The animals can be used for demonstrating compounds intended for the treatment of Alzheimer's disease.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: April 20, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Caty Casas Louzao, Patrick Benoit, Laurent Pradier, Gunter Tremp, Jean-Michel Itier, Véronique Blanchard-Bregeon
  • Prostaglandin receptor protein
    Patent number: 7488799
    Abstract: Described herein is a novel member of the prostanoid receptor family, a guinea pig prostaglandin D2 receptor. Described are the receptor, the nucleic acid that encodes it, and various uses for both.
    Type: Grant
    Filed: January 9, 2007
    Date of Patent: February 10, 2009
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Ashfaq Parkar, Paul August, Theresa Kuntzweiler, Mohamad Ali Ardati, Namadev Baskaran
  • Process for identifying modulators of G-protein-coupled receptors
    Patent number: 7378252
    Abstract: The invention relates to a widely applicable process for identifying chemical compounds, which modulate G-protein-coupled receptors, by means of novel hybrid G-proteins with broad receptor specificity and very high expression and also to chemical compounds which can be identified by such a process.
    Type: Grant
    Filed: February 17, 2005
    Date of Patent: May 27, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventor: Evi Kostenis
  • MEKK1-interacting FHA protein 1 (MIF1)
    Patent number: 7364871
    Abstract: The present invention relates to a novel protein of the MEKK signal transduction pathway, and the gene encoding it. The invention further relates to diagnostic and therapeutic uses of the protein or the gene, and to methods of screening for agonists or antagonists of the protein, particularly with respect to MEKK activity. In particular, the invention provides a gene encoding MIF1, the MIF1 protein, and antibodies that specifically bind MIF1. MIF1 and the MIF1 gene can be used in screening assays, particularly to identify agonists and antagonists of MIF1 interaction with MEKK, and thus modulators of the MEKK signal pathway. MIF1 gene (or cDNA) can also be delivered to cells, e.g., for in vitro screening or testing, or in vivo or ex vivo for gene therapy.
    Type: Grant
    Filed: April 14, 2005
    Date of Patent: April 29, 2008
    Assignee: Aventis Pharma S.A.
    Inventors: Christophe Marcireau, Marie-Christine Multon, Valerie Polard-Housset
  • Prostaglandin receptor protein and methods of use thereof
    Patent number: 7183062
    Abstract: Described herein is a novel member of the prostanoid receptor family, a guinea pig prostaglandin D2 receptor. Described are the receptor, the nucleic acid that encodes it, and various uses for both.
    Type: Grant
    Filed: December 30, 2003
    Date of Patent: February 27, 2007
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Ashfaq Parkar, Paul August, Theresa Kuntzweiler, Mohamad Ali Ardati, Namadev Baskaran
  • Method for treating neurological conditions and inducing immunosuppression with cephaibols
    Patent number: 7041649
    Abstract: Embodiments of the present invention relate to administering cephaibols to treat conditions of the nervous system and to treat those conditions in which suppressing the immune system would have beneficial effect.
    Type: Grant
    Filed: May 21, 2003
    Date of Patent: May 9, 2006
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Mathias Schiell, Laszio Vertesy, Joachim Wink, Brigitte Schlegel, Albert Haertl, Udo Graefe